Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

52.15USD
3:59pm EST
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$52.16
Open
$51.97
Day's High
$52.33
Day's Low
$51.68
Volume
324,584
Avg. Vol
311,764
52-wk High
$63.40
52-wk Low
$46.65

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $8,020.95
Shares Outstanding(Mil.): 153.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes

* PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2A7WmiG) Further company coverage:

Dec 05 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Nov 27 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Nov 27 2017

BRIEF-Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr

* ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION‍​ - SEC FILING

Nov 27 2017

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

Nov 16 2017

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

Oct 26 2017

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* ‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​

Oct 26 2017

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

Jul 27 2017

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

Jun 29 2017

Competitors

Earnings vs. Estimates